Patient Global Impression of Severity Data

For your patients with 4-14 MHDs per month,

Patients reported a significantly greater reduction in the severity of their disease with Emgality, on average, over Months 4 to 6 (p=0.002)1,4

Mother Daughter Lifestyle image
Emgality significantly improved patients’ impression of the severity of their disease vs placebo, on average, over Months 4 to 6 (p=0.002)<sup>4</sup> graphic
  • EVOLVE-1: Mean change from baseline in PGI-S score was -1.59 for Emgality vs -1.27 for placebo. LS mean difference: -0.32 (p=0.002)a
  • EVOLVE-2: Mean change from baseline in PGI-S score was -1.22 for Emgality vs -0.94 for placebo. LS mean difference: -0.29 (p=0.002)a

Mean change from baseline in the PGI-S score over Months 4 to 6.4

aEVOLVE-1: Emgality 120 mg (N=189), placebo (N=377); EVOLVE-2: Emgality 120 mg (N=213), placebo (N=396).

See Study Design for EVOLVE-1 and EVOLVE-2

Indication and Important Safety Information
Indication

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the pen and prefilled syringe.


GZ HCP ISI 27SEP2018